Industry verticals
Warm Introductions in Healthcare and Life Sciences: How the HCP Access Channel Works
Pharmaceutical, medtech, and life sciences commercial teams operate in one of the most regulated HCP access environments in any industry. Direct promotional contact between manufacturer representatives and healthcare professionals is subject to the Sunshine Act in the US, the EFPIA code in Europe, and institutional credentialing systems that have progressively reduced unsolicited commercial access over the past decade. In this environment, warm introductions (peer-to-peer physician exchange, KOL-facilitated discussions, and medical affairs relationships that pre-warm commercial access) have become the primary channel through which new therapies and devices reach clinical adoption. Understanding how the introduction channel works in healthcare, and the compliance framework that governs it, is the foundation of effective life sciences commercial strategy.
Why HCP access has shifted to relationship-based channels
Four structural forces have reshaped how pharmaceutical and medical device companies reach healthcare professionals over the past fifteen years. Together they have made direct commercial access harder, and peer-mediated warm introduction more important.
The Physician Payments Sunshine Act (US)
Enacted as part of the Affordable Care Act in 2010, the Sunshine Act requires pharmaceutical and medical device manufacturers to track and publicly report all transfers of value to physicians, including meals, speaking fees, consulting payments, and research funding. The CMS Open Payments database publishes this data annually. The effect on commercial access was significant: anything that could appear on the public record as a promotional payment became a liability for physicians concerned about reputational exposure, and manufacturers became more cautious about activities that could be construed as inducements. Peer-to-peer scientific exchange, where a physician speaks to a colleague in a non-promotional capacity, is not a transfer of value from the manufacturer and is therefore not reported, which is one structural reason the KOL introduction pathway has grown in importance relative to direct company-sponsored access.
The EFPIA Code of Practice (Europe)
The European Federation of Pharmaceutical Industries and Associations code governs interactions between pharmaceutical companies and healthcare professionals across member countries. The EFPIA code prohibits gifts and hospitality that go beyond what is necessary for scientific or educational purposes, limits sponsorship of HCP attendance at congresses to strictly defined conditions, and requires that any transfer of value be disclosed. Many EU member states have national transpositions of the code with additional restrictions. As in the US, the practical effect is that direct company-initiated commercial contact with HCPs operates under tight constraints, and peer introduction through the professional medical community is a less regulated, more trusted access channel.
Institutional gatekeeper systems
Hospital systems, integrated delivery networks, and group purchasing organisations have added administrative layers to HCP access that are independent of regulatory requirements. Many hospital systems now require that pharmaceutical representatives register through a centralised credentialing system (Reptrax, Vendormate, or equivalent), which tracks visit frequency and limits unsolicited access. Academic medical centres often require that any rep visit be pre-approved by the relevant department. These institutional controls mean that even where regulatory constraints would permit a commercial visit, operational access is often blocked. The result is that the most reliable pathway to HCPs in restricted settings is through a colleague who already has a trusted relationship with that physician: a peer, a KOL, or a medical affairs professional whose role explicitly permits scientific exchange visits.
The rep-access decline
IQVIA access and engagement research has documented a sustained decline in HCP accessibility to pharmaceutical sales representatives over the past decade. A significant proportion of physicians in primary care and hospital settings are classified as "access restricted", meaning they see fewer than a quarter of the representatives who attempt to contact them. The decline reflects a combination of time pressure on physicians, the credentialing and scheduling overhead of managing rep visits, and a growing preference among many HCPs to receive medical information through peer and scientific channels rather than commercial ones. In this environment, a warm introduction from a respected colleague is not just preferred. It is often the only viable entry point.
Three warm introduction pathways in life sciences commercial
The access constraint does not eliminate commercial success; it redirects the channel. The manufacturers who reach HCPs most effectively do so through three distinct peer-mediated introduction pathways, each operating under its own mechanics and compliance requirements.
KOL-to-peer introduction
A key opinion leader, a physician or researcher with significant influence over peer practice in a therapeutic area, speaks to a colleague about a product or clinical approach in a scientific context. The KOL may present data at a clinical meeting, discuss a patient case, or directly recommend that a colleague investigate a new therapy. From the recipient physician’s perspective, this is scientific peer communication, not a commercial contact. The credibility transfer is high because the KOL has clinical standing that the manufacturer’s representative does not.
What drives it
Medical affairs investment in KOL identification, scientific exchange, and speaker development. Manufacturers identify KOLs through publication records, trial investigator roles, society leadership, and referral patterns. The investment is in building genuine scientific relationships with these physicians (through advisory board participation, investigator-initiated study support, publication support, and speaker programme development) so that the KOL has both the knowledge and the inclination to discuss the product with peers.
Compliance note
KOL speaker programmes and advisory boards must be structured around legitimate scientific need (fair market value compensation, documented deliverables, reasonable number of engagements). The EFPIA code and PhRMA code both require that consultancy arrangements not be used as a disguised mechanism for inducing prescriptions.
Physician-to-physician peer exchange
A physician who has clinical experience with a product, whether as a trial investigator, an early adopter, or a participant in a speaker programme, discusses that experience with a colleague who is making a treatment decision. This is the most authentic form of warm introduction in healthcare: a peer sharing clinical experience rather than a manufacturer presenting commercial data. It is also the channel with the highest credibility weight, because the connector is vouching from firsthand patient experience.
What drives it
Product performance in real clinical practice, and the quality of a manufacturer’s support for the treating physicians who use the product. A physician whose patients have had good outcomes with a product, and who has been well-supported by the company’s medical affairs and customer support teams, is the most credible peer connector available. This is why patient outcomes and physician experience are the foundation of the peer introduction channel: the commercial team cannot manufacture a peer recommendation, but it can create the conditions in which one becomes likely.
Compliance note
Peer exchange that occurs independently between physicians, without company instigation, is outside regulatory scope. Company-facilitated peer exchange programmes, where the manufacturer funds educational events or connects physicians deliberately, must be documented, educational in content, and compliant with fair market value requirements.
Medical Science Liaison (MSL) scientific exchange
The MSL is a field-based medical affairs professional whose primary function is scientific exchange with HCPs and KOLs. Unlike a sales representative, the MSL does not carry a promotional message and is not measured on prescribing outcomes. The MSL’s value to the HCP is access to clinical trial data, health economics evidence, and pipeline information through a channel that is explicitly scientific rather than commercial. In practice, the MSL also functions as a warm introduction facilitator: an HCP who has a trusted relationship with an MSL is more likely to engage with subsequent commercial contacts from the company, and an MSL who introduces a commercial team member to a KOL is providing a contextual warm introduction that a cold commercial contact cannot replicate.
What drives it
The quality of the scientific exchange the MSL provides and the consistency of the relationship. MSLs who bring genuine clinical value (new data, connections to clinical trials, access to global experts) build relationships that persist through product life cycles and create the conditions for commercial team access that would not otherwise exist.
Compliance note
The boundary between MSL (non-promotional) and commercial activities must be maintained rigorously. MSLs should not be directed by commercial teams or measured on commercial outcomes. The separation between medical affairs and commercial functions is a regulatory requirement in many markets and a professional norm in all of them.
Medical affairs as warm introduction infrastructure
The Medical Science Liaison function represents one of the most systematic warm introduction programmes in any industry, though it is rarely described in those terms. MSLs are field-based medical affairs professionals who build and maintain scientific relationships with KOLs and high-influence HCPs across a therapeutic area. Their mandate is scientific exchange, not commercial promotion, and they are deliberately separated from commercial management to maintain that distinction.
The commercial value of this separation is paradoxical: precisely because MSLs are not commercial, HCPs engage with them more openly. An oncologist who will not see a sales representative for a new immunotherapy will see an MSL to discuss the mechanism of action, the trial design, and the adverse event management data, because the conversation is scientific rather than promotional. Over time, that scientific relationship creates the conditions for commercial engagement. The HCP who has had substantive scientific exchanges with a company’s MSL, who has participated in an advisory board, or who has been a trial investigator has a fundamentally different relationship with the company than one who has received only commercial contacts.
For life sciences companies, the implication is that medical affairs investment is partly a warm introduction investment. Companies that build strong MSL programmes, invest in KOL scientific relationships, and support investigator-initiated research are building the relationship capital that enables commercial access over time. The time horizon is longer than in most industries; the relationship between a company and a KOL may take years to develop before it generates consistent peer-level advocacy. But the return is a channel that direct commercial investment cannot buy.
The practical implication for commercial teams is that they should understand their MSL team’s KOL map and use it to sequence commercial engagement strategically. An account in which the MSL has an established scientific relationship with three senior physicians is a fundamentally different commercial opportunity than an account where no prior relationship exists. The warm introduction channel in healthcare does not work by asking the MSL to introduce a representative, which would blur the promotional line. It works by ensuring that the scientific relationships the MSL has built create the context in which commercial contacts are received as part of a known company relationship rather than as cold outreach from an unknown.
The compliance framework for warm introductions in healthcare
The regulatory architecture around HCP engagement does not prohibit warm introduction. It defines the conditions under which it can operate. Four principles govern compliant warm introduction practice in life sciences.
Fair market value for all engagements
Any compensation provided to a KOL for speaking, advisory, or consulting services must reflect the fair market value of the time and expertise provided, not the prescribing volume or potential prescribing influence of the physician. Most manufacturers maintain formal FMV rate cards developed by independent consulting firms, with tiers based on specialty, academic credentials, and publication record. Engagements above a defined threshold typically require additional compliance review. The purpose of the FMV requirement is to ensure that consultant compensation cannot be construed as an indirect inducement to prescribe.
Transfer of value documentation and disclosure
In the US, all transfers of value to physicians and teaching hospitals are reported to CMS through the Open Payments system. In Europe, the EFPIA code requires country-level disclosure of transfers of value to HCPs and healthcare organisations. In practice, this means that every speaker fee, advisory board payment, meal, travel reimbursement, and research grant involving a physician is a matter of public record. Commercial teams and medical affairs teams must maintain rigorous documentation of all engagements, and many manufacturers have moved to conservative standards that reduce borderline expenditure to avoid adverse public reporting.
Prohibition on quid-pro-quo arrangements
No transfer of value, whether a speaking fee, advisory board participation, a trial grant, or any other benefit, may be conditioned on prescribing behaviour, or given with the expectation that prescribing will follow. This prohibition is enforced through the Anti-Kickback Statute in the US, the EU pharmaceutical directives, and national anti-corruption laws in most markets. The practical implication for warm introduction strategy is that the causal chain must run from scientific evidence to clinical adoption, not from payment to introduction to prescribing. Manufacturers who build commercial strategies around relationships that are genuinely grounded in scientific exchange are on firm ground; those who attempt to use financial arrangements as indirect purchase of peer access are exposed to significant legal risk.
Separation of promotional and non-promotional activities
Pharmaceutical regulation in most markets draws a clear line between promotional communications (directed at inducing prescribing) and non-promotional activities (scientific exchange, education, publication). The materials, personnel, and approval processes for each must be separate. Promotional materials require regulatory approval (the PI and approved claims); scientific exchange materials do not, but must be genuinely scientific in nature and balanced in content. Warm introduction channels that operate through the non-promotional track (MSL exchange, investigator meetings, advisory boards, medical education) are subject to different regulatory constraints than commercial visits, and must not be used as a workaround to deliver promotional messages.
What this means for commercial leaders
The access environment in life sciences has stabilised around a set of channels that reward relationship investment and penalise transactional outreach. The companies that adapt most effectively share several characteristics.
They invest in medical affairs as a genuine parallel function rather than a commercial tool, and they maintain the medical-commercial firewall as a structural asset rather than a compliance burden. A strong medical affairs team that has independent credibility with the KOL community is more valuable to the commercial team than a direct access programme, precisely because it is not commercial.
They identify and invest in KOL relationships in the right therapeutic sub-segments: not just the highest-prescribing physicians overall, but the physicians whose clinical opinions shape how their peers practice. A single well-respected academic investigator who discusses product data at a regional clinical meeting may influence more prescribing decisions than a hundred commercial visits to individual practitioners.
They close the loop systematically. The warm introduction channel in healthcare, like in every other domain, depends on the relationship being maintained after the introduction. Commercial teams that provide exceptional support to trial investigators, that loop back to advisory board physicians with how their input shaped product development, and that maintain genuine relationships with the physicians who champion their products build the kind of relationship capital that generates sustained peer advocacy, not a single referral.
The constraint is real. The Sunshine Act, the EFPIA code, and institutional credentialing systems have permanently changed what direct commercial access looks like in healthcare. But the channel constraint has not changed the fundamental dynamic: HCPs adopt new therapies when they trust the clinical evidence and when respected colleagues they trust have used them with good patient outcomes. Building the relationships that create that peer credibility is the work of life sciences commercial and medical affairs alike.
Frequently asked questions
How does HCP access restriction vary by specialty and setting?
Access restriction varies significantly across specialties and practice settings. Hospital-based physicians and academic medical centre clinicians are typically the most restricted: many major academic centres require credentialing, appointment scheduling, and departmental approval for commercial visits. Primary care physicians in the US and Europe have also become progressively more restricted over the past decade as their time is under more pressure and their practices have been absorbed into larger health systems with centralised access policies. Specialists who see fewer patients but make higher-impact prescribing decisions, such as oncologists, rheumatologists, and immunologists in targeted disease areas, are often both more accessible to medical affairs relationships (because the clinical complexity justifies engagement) and more restricted to commercial contacts (because the prescribing stakes are higher). In contrast, community-based specialists and private practitioners in some markets remain relatively accessible to commercial visits.
What is the difference between a KOL engagement and a standard speaker programme?
A KOL (key opinion leader) engagement typically involves a more senior, higher-influence physician in a relationship that spans multiple activities: advisory board participation, investigator roles in clinical trials, publication collaboration, and potentially speaker activities. KOL relationships are long-term investments in physicians who shape practice in a therapeutic area. They are identified through publication records, conference leadership, and peer citation rather than geographic proximity or prescribing volume. A speaker programme, in contrast, typically involves a broader group of physicians who have training and experience with a product and speak to peer audiences about clinical evidence and their own experience. Both are subject to fair market value and disclosure requirements, but they serve different functions: KOL relationships build the scientific credibility that influences guidelines and peer norms; speaker programmes activate peer-to-peer exchange at scale.
How should a commercial team think about the boundary with medical affairs?
The commercial-medical boundary is both a regulatory requirement and a practical constraint. Medical affairs functions (MSLs, medical education, health economics, publication planning) are non-promotional by definition: they operate on the scientific, educational side of the regulatory line and must not be directed by or accountable to commercial management. The commercial benefit of the medical-commercial firewall is that it preserves the credibility of the medical channel: an HCP who believes that an MSL visit is genuinely scientific exchange is more likely to engage with substantive data than one who suspects the MSL is a commercial visit in disguise. Practically, this means commercial teams should think of medical affairs relationships as creating the conditions for commercial engagement (building scientific credibility, mapping the KOL landscape, generating clinical evidence) without attempting to direct the content of those relationships or using medical contacts as commercial surrogates.
How does the warm introduction channel work in medical device and diagnostics versus pharma?
Medical device and diagnostics companies operate under somewhat different regulatory frameworks (FDA 510(k) and PMA in the US; EU MDR/IVDR; BSI marking), but the commercial dynamics of HCP access are similar in important ways. The physician-to-physician peer endorsement is at least as powerful in device adoption as in pharma. Adoption of a new surgical technique or a new diagnostic platform is heavily influenced by what respected colleagues have done in clinical practice, especially early adopters who trained with the technology. The MSL equivalent in device and diagnostics is often called a clinical specialist or clinical education manager, and plays a similar non-promotional scientific exchange role. Device companies also benefit from proctoring relationships (where an experienced user trains a less experienced colleague at the new user’s institution), which are explicitly structured as physician-to-physician peer education rather than company-sponsored promotion.
What does a compliant peer exchange programme look like in practice?
A compliant peer exchange programme, sometimes called a peer-to-peer educational programme or local clinical meeting, typically has several elements: independent educational content that is not solely promotional in nature; qualified faculty (physicians with clinical experience with the subject matter) engaged at fair market value with documented deliverables; an audience of physicians who have a genuine clinical reason to attend; and documentation of the programme in the company’s transfer-of-value records. Many manufacturers also maintain a process for HCP-initiated requests for educational meetings, which are held to a somewhat different standard than company-initiated events. The key compliance markers are: fair market value, documented scientific or educational purpose, audience qualification, and absence of quid-pro-quo arrangements. Companies that apply these markers rigorously build peer exchange programmes that are both regulatory-sound and scientifically credible.